HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease.

Abstract
After the discovery of formoterol and salmeterol, new candidates for long-acting beta2-adrenoceptor agonists (LABAs) have emerged from various companies. In particular, once-daily beta2-adrenoceptor agonists such as arformoterol, carmoterol, indacaterol, GSK-159797, GSK-597901, 159802, 642444 and 678007 are under development for the treatment of asthma and chronic obstructive pulmonary disease. The majority of these compounds are (R,R)-isomers in order to control desensitisation and accumulation. Several options for combination products are currently being evaluated in parallel with the development of these ultra LABAs. Once-daily dosing of an ultra LABA would be a significant convenience and probably a compliance-enhancing advantage leading to improved overall clinical outcomes in patients with asthma and chronic obstructive pulmonary disease. The only limits set for the development of a LABA with a new product profile are medical needs and marketing opportunities.
AuthorsMario Cazzola, Maria Gabriella Matera, Jan Lötvall
JournalExpert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 14 Issue 7 Pg. 775-83 (Jul 2005) ISSN: 1744-7658 [Electronic] England
PMID16022567 (Publication Type: Journal Article, Review)
Chemical References
  • Adrenergic beta-2 Receptor Agonists
  • Adrenergic beta-Agonists
  • Delayed-Action Preparations
  • Drugs, Investigational
  • Receptors, Adrenergic, beta-2
Topics
  • Adrenergic beta-2 Receptor Agonists
  • Adrenergic beta-Agonists (administration & dosage, chemistry, pharmacology)
  • Animals
  • Asthma (drug therapy, metabolism)
  • Delayed-Action Preparations (chemistry, pharmacology, therapeutic use)
  • Drug Administration Schedule
  • Drugs, Investigational (chemistry, pharmacology, therapeutic use)
  • Humans
  • Pulmonary Disease, Chronic Obstructive (drug therapy, metabolism)
  • Receptors, Adrenergic, beta-2 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: